GlassScriptPhysician profile
Jyothsna Kodali
NPI 1710965215
$1,247.36
in general payments reported to CMS, 2019-2025
25 companies · $609 in 2025
The $609 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.35 · 2020: $63.98 · 2021: $18.94 · 2022: $92.28 · 2023: $262 · 2024: $109 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975 · Education: $4.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.38 |
| Education | $4.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $196.25 | 2023-2025 | Filspari |
| Fresenius USA Marketing, INC. | $169.54 | 2022-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $163.62 | 2020-2025 | Farxiga |
| Amgen INC. | $146.14 | 2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $67.84 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Scpharmaceuticals INC. | $44.07 | 2025 | |
| Calliditas Therapeutics US INC. | $42.57 | 2023 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $30.08 | 2022 | |
| Alexion Pharmaceuticals, INC. | $28.07 | 2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $27.37 | 2025 | Acthar |
| Vifor Pharma, INC. | $23.73 | 2023 | Veltassa |
| Shield Therapeutics INC | $23.35 | 2025 | |
| Horizon Therapeutics Plc | $21.94 | 2022 | |
| Glaxosmithkline, LLC. | $21.55 | 2023 | Benlysta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $21.31 | 2025 | Paradise Ultrasound Renal Denervation System |
| Inspire Medical Systems, INC. | $21.05 | 2025 | Inspire |
| Aurinia Pharma U.S., INC. | $19.58 | 2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $19.10 | 2024 | |
| Baxter Healthcare | $18.94 | 2021 | |
| Allergan, INC. | $18.67 | 2019 | |
| Ardelyx, INC. | $18.06 | 2025 | Ibsrela |
| Vantive US Healthcare LLC | $16.23 | 2025 | Renal - Pd |
| Kyowa Kirin, INC. | $14.62 | 2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyothsna Kodali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.